Vecuronium in renal failure.
Neuromuscular blockade during surgery was provided with vecuronium in 24 adult patients in end-stage renal failure and in 21 normal patients who served as controls. Dose response curves were constructed which showed that the effective doses required to produce 50, 90 and 95 per cent neuromuscular blockade in patients with renal failure were 27.5, 43 and 49 micrograms X kg-1 respectively. These were not significantly different from the doses of 31, 49 and 57 micrograms X kg-1 in the normal patients. Repeated small doses of 0.01 mg X kg-1 had a significantly longer duration of action and were associated with some cumulation in the renal failure group. Recovery from the block occurred rapidly after neostigmine, was no different in renal failure and was not associated with recurarization. It is concluded that, when given to subjects in renal failure, vecuronium offers advantages over established agents such as shorter duration of action and easy reversibility.
D000328:Adult; D000768:Anesthesia, General; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008657:Metabolic Clearance Rate; D009466:Neuromuscular Blocking Agents / Q000097:blood*; D009469:Neuromuscular Junction / Q000187:drug effects; D010197:Pancuronium / Q000031:analogs & derivatives* / Q000097:blood; D009435:Synaptic Transmission / Q000187:drug effects; D014673:Vecuronium Bromide
D009466:Neuromuscular Blocking Agents; D014673:Vecuronium Bromide; D010197:Pancuronium